Skip to Content
Home > Services > Cancer > Clinical Research Trials > Clinical Trial Search > Detail
<< Back to Results
This randomized clinical trial studies prophylactic colony-stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony-stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony-stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony-stimulating factor may help doctors use colony stimulating factor when it is needed.
Thank you for your feedback!
More Events >>
Get the latest news on the health topics that matter most to you.
© 2019 Spartanburg Regional Healthcare System. All Rights Reserved.